투자판단관련주요경영사항(임상시험결과) (진행성 핵상마비 치료제로서 GV1001의 국내 2a상(GV1001-PSP-CL2-011) 임상시험의 연장 임상시험 의 최종결과보고서(CSR) 수령)[코]
Received: 4/9/2026 · Reporter: 젬백스
A summary for this filing type is not yet available. Please refer to the original DART filing.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 101 filings
- Same category
- 59 filings
- Previous same-category filing
- 7/20/2026
- Corrections / withdrawals
- 26 filings
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).